Articles
Large Molecules in Drug Development: A Growing Market Demand
What are large molecules?
In drug development, molecules are classified by molecular weight into small molecules and large molecules also known as biologics. Large molecules range from about 2,000 to 2,000,000 g/mol, making them much larger and more structurally complex than small molecules. They are often derived from biological sources and are central to modern therapeutics.
Key categories:
- Proteins (e.g., enzymes, interferons, insulin)
- Monoclonal antibodies (mAbs), widely used in oncology and immunology
- Antibody-drug conjugates (ADCs), combining targeting with cytotoxic payloads
- Oligonucleotides, such as mRNA or antisense therapies
- Polymers and other complex biomaterials
Biologics are increasingly pivotal in pharmaceutical innovation, with about 30–40% of FDA-approved drugs now biologics, underscoring strong and growing market demand.
Why are large molecules difficult to analyze?
Large molecules bring unique analytical challenges not typically seen with small molecules, including:
- Structural complexity
- Heterogeneity
- Stability and degradation issues
- Complex sample preparation
For example, proteins and monoclonal antibodies often need to be digested into smaller peptides for mass spectrometry analysis. Similarly, advanced therapies like antibody–drug conjugates (ADCs) may require separate quantification of multiple components (antibody, payload, linker), adding to analytical complexity. This growing complexity highlights the limitations of conventional bioanalytical approaches.
Why is LC-MS/MS transforming large-molecule analysis in drug development?
While ligand-binding assays such as ELISA have long been used for large molecule quantification, LC‑MS/MS has become a strategic alternative, better aligned with today’s industrial requirements, which are:
- Higher specificity: Quantification is highly accurate relative to ELISA variability; MRM provides precise and reliable data.
- Reproducibility: Rapid, high-throughput analysis with consistent results across systems using validated bioanalytical methods.
- Multiplexing capability: Ability to quantify multiple large molecules in a single run.
- Lower costs: Less labor-intensive, no expensive reagents, and minimal human error.
- Low limit of qualification: Picogram-level sensitivity.
This makes LC-MS/MS particularly suited for pharmacokinetics (PK), biomarker analysis, and complex biologic characterization.
Biotrial’s expertise in large-molecule quantification using HPLC-MS/MS
Biotrial’s bioanalytical service specializes in quantifying and analyzing molecules with LC-MS/MS. We bring extensive experience in large-molecule quantification via HPLC-MS/MS across preclinical and clinical programs, delivering robust method development, optimization, and GLP-compliant validation.
Conclusion
As large molecules drive the next wave of therapeutic innovation, reliable and highly specific bioanalytical strategies are essential. LC-MS/MS remains the gold standard, offering exceptional sensitivity, accuracy, and multiplexing capabilities for complex biologics. With deep scientific expertise and validated LC-MS/MS platforms, Biotrial supports biopharmaceutical developers from preclinical studies through GLP-compliant clinical programs.
Partner with Biotrial to accelerate your large molecule development and transform analytical complexity into confident, decision-ready data.
